Access to anti-retroviral drugs, male in Panama

Panama: Access to anti-retroviral drugs, male was 72.0% in 2024. ◆ Volatile

Latest (2024)
72.0%
Change on year
up 1.4%
World rank
65th
of 141 countries
All-time high
72.0%
in 2024
All-time low
6.0%
in 2000
Years of data
25
2000–2024

Access to anti-retroviral drugs, male in Panama, 2000–2024

0204060802000201220242000: 6 %2001: 8 %2002: 10 %2003: 12 %2004: 13 %2005: 15 %2006: 17 %2007: 19 %2008: 20 %2009: 26 %2010: 27 %2011: 29 %2012: 34 %2013: 36 %2014: 39 %2015: 41 %2016: 47 %2017: 52 %2018: 55 %2019: 57 %2020: 56 %2021: 55 %2022: 69 %2023: 71 %2024: 72 %

Source: UNAIDS estimates. Measured in %.

Analysis

In 2024, access to anti-retroviral drugs, male in Panama stood at 72.0%. That is the highest value across all 25 years on record.

The figure is up 1.4% on the previous year and up 84.6% over ten years.

Over the whole period, access to anti-retroviral drugs, male in Panama peaked at 72.0% in 2024 and was at its lowest, 6.0%, in 2000.

Panama ranks 65th of 141 countries on this measure, in the middle of the range.

The series is highly variable year to year, so single readings are best treated with caution.

Access to anti-retroviral drugs, male in Panama, year by year

Annual values for Access to anti-retroviral drugs, male (%) in Panama, 2000 to 2024.
Year % Change
2000 6.0%
2001 8.0% +33.3%
2002 10.0% +25.0%
2003 12.0% +20.0%
2004 13.0% +8.3%
2005 15.0% +15.4%
2006 17.0% +13.3%
2007 19.0% +11.8%
2008 20.0% +5.3%
2009 26.0% +30.0%
2010 27.0% +3.8%
2011 29.0% +7.4%
2012 34.0% +17.2%
2013 36.0% +5.9%
2014 39.0% +8.3%
2015 41.0% +5.1%
2016 47.0% +14.6%
2017 52.0% +10.6%
2018 55.0% +5.8%
2019 57.0% +3.6%
2020 56.0% -1.8%
2021 55.0% -1.8%
2022 69.0% +25.5%
2023 71.0% +2.9%
2024 72.0% +1.4%

Averages by decade

DecadeAverage LowestHighest Years
2000s 14.6% 6.0% 26.0% 10
2010s 41.7% 27.0% 57.0% 10
2020s 64.6% 55.0% 72.0% 5

Countries ranked near Panama

  1. 62 Chile 73.0% compare
  2. 62 Myanmar 73.0% compare
  3. 62 United Arab Emirates 73.0% compare
  4. 65 Eritrea 72.0% compare
  5. 65 Georgia 72.0% compare
  6. 65 Tajikistan 72.0% compare

See the full ranking of 160 places →

More gender data for Panama

All data for Panama →

Frequently asked questions

What is access to anti-retroviral drugs, male in Panama?
Access to anti-retroviral drugs, male in Panama was 72.0% in 2024, according to UNAIDS estimates.
What is the highest access to anti-retroviral drugs, male recorded in Panama?
The highest recorded value was 72.0% in 2024.
What is the lowest access to anti-retroviral drugs, male recorded in Panama?
The lowest recorded value was 6.0% in 2000.
How does Panama rank for access to anti-retroviral drugs, male?
Panama ranks 65th out of 141 countries with data for 2024.
Is access to anti-retroviral drugs, male rising or falling in Panama?
Over the last ten years it is up 84.6%. The long-run trend across the full record is volatile.
Where does this Panama data come from?
The figures come from UNAIDS estimates, published as part of Access to anti-retroviral drugs, male (%). Statizoid updates them automatically from the source API.

Download this data

CSV · JSON — 25 observations, free to reuse under CC BY 4.0 (World Bank Open Data).

Share, cite or embed this page

Cite this page

Access to anti-retroviral drugs, male in Panama. Statizoid, drawing on UNAIDS estimates. Retrieved 08 September 2026, from https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-male-percent/panama/

Embed or link this data

Paste this into a page to link back to these figures. The data itself is free to reuse under CC BY 4.0 (World Bank Open Data); please keep the attribution.

<a href="https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-male-percent/panama/">Access to anti-retroviral drugs, male in Panama</a> — Statizoid

About this data

Indicator
Access to anti-retroviral drugs, male (%)
Unit
%
Source
UNAIDS estimates
Licence
CC BY 4.0 (World Bank Open Data)
Coverage
160 places, 3,923 data points, 2000–2024
Last refreshed

The percentage of adult males living with HIV who are receiving antiretroviral therapy.